Analyst Upgrades Catalyst Pharmaceuticals to Overweight with New Price Target of 34
On March 1, 2024, Cantor Fitzgerald analyst Charles Duncan reaffirmed his positive stance on Catalyst Pharmaceuticals (NASDAQ:CPRX), upgrading the stock ...
Tag: CPRX
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
